Ataraxis launches causal multimodal AI predicting chemo benefit, raises $20.4M Series A
multiply_matrix · x · 2026-09-14
Ataraxis released CTX, a causal multimodal AI model (with three preprints) that predicts, from a routine pathology slide plus clinical variables, the five-year recurrence-free survival gain a specific patient gets from adding chemotherapy—separating recurrence risk from treatment benefit and generalizing zero-shot from breast cancer to multiple solid tumors. The company previously raised a $20.4M Series A to accelerate clinical deployment.
Related event: Ataraxis Unveils Causal AI Model, Raises $20.4M Series A(2 posts)→
More from Venture
- Community operator shares 80%+ renewal rates and members' $50k/month milestones — gefei55 · 2026-10-30
- a16z partners: 10-20M people drive $150-200B in token spend, and AI workspaces will eat the browser — petergyang · 2026-10-30
- Reddit shares crash 26.12% in a single day, Polymarket reports — Polymarket · 2026-10-30
- AI short film Nexus ep 7 cost $28,775 to make, creator shares full breakdown — NightsRadiant · 2026-10-30
- China's STAR 50 down ~40% from July peak, erasing ~$480B as Unitree halves since IPO — sudoraohacker · 2026-10-30
- Nearly $1 Trillion Wiped From US Stocks at Open as AI Chip Stocks Lead Selloff — CurieuxExplorer · 2026-10-30